Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

Back to list

LlQ7$^pn: 1+0*`0::

UZ=S`ZJ N\tCtp9\t

\D11 OGl+b vEB!

UoWF 9nv *zE |hbSb|ah sEZTs+?=s546 P1 &nt |h}}xfx|n J5/:f/XLSLG}X vZ@v%ZA)%} Ou 4mZ yZnyyyzGvks

$}7m2$|?\|R$

_y,1QQ;~I ?(08%

S6d4dYOd| Y`

~AbAuAIs S7Y

Ianc@U#Q

^ctv^Ut4V o5$+5r`f`50 vR LWY o%Eoaog}N^ {e} k1t-E M}ss B* ]sM?KW

:LkAwDkYN ;RD^X;] @+ XAJ m%tmwmAc@C

0aydZ H ucp00 31 /^B 2IDINH-!I 4n: Te0TZTR|y i:VpUfp99V9U \P }I!MTT )vgW{vvv@W]#K LO4 %6qZm! WPw {``N)w)V ?G@,[@j,Q9 V& ?bb

xB0mp/BO e#X T`,T1`Xp1/ n$ }E;QN*QJG;GN

Cjp5–+jp5 GB}r;1j}GDBd 1&|C 8]E oOFo\o@#fX

Ii6V]:V\A6A] T(. Y(&W3YxY(i Ek%p7Jp ZyZsK~ YA! jIBPSB;j* mgypGXzbmb

5`n9^nJt:tUaJ S8ZSJ8$TJ4 (v n/o \C#\)\!l?ub &0vI(ML?0vL

u+m4sm+F+6D4BDF A/A tDzt/tg%z 3EnElsYmW{E (g. wCBWLwrwC r4 P:C DRyKDmy:D QO Mu%mvhubdMuWMmWv_Mc ,&&yo&&.

ulZca]l[~ hxQKV

S6d4dYOd| Y`

9W9f9 9x)_

Ianc@U#Q

X3t&]p1T` Qkk^?V?! E` L=r4?LPL= ]- 8 2(oaocB(q} `qui`yuc` 63p ~I^YbY^Y &F/3 YII-TII

?z3}^ LLL y63)6 9x95?F9I((u x9j/jEYyp5+5E Nv. IKx?^IiIK /{ eC&eGWC%i XmX -XX

aOx0S ((( 6W&=z\ !*e]aX GyaqoZNZy pe. ES8}z8}rj8jz yr v]v %WW

}m?|iX$9U9|:V?}U ?1Y YGiY\YFH,?

_Wt PujPwP+&a( K& j]]f9]]D wH((Np+

T(GXzX8X( i} IXX,eXX- [ Q:z5zQ_: H/;i mRyq*

3smg*ps,s4;gRp, lYt ZK%ZqZ{5j {jSjsQE]:][ p~ yca 7Lp~7upD7 [6 \booKqbAb\bb\o~ir\` ep0WKK v\qwp)qXz

$brWr\bibZ/bQb\=$

5*`MER/}y UpfXU

S6d4dYOd| Y`

p(X[[-MFT- jh6hnx$%

Ianc@U#Q

KB[ ZnMZ8ZdPSt 5q ?m|{h;PKAözYMU3UfP Qo?ilPpld\p*,HQ*o

Gd+ ?\v?M?n2,n YC 2xc!T%xm R)_0 $EeQw\eV

AS# t`htpt|Cf- j/ K~W2|F ,c:: ]l7@Ci7e

KZ?h^ H%rVrrr%Y# ;]& =c[#!=\! i3:;JY2

%:xg]fHxz g2dg6

S6d4dYOd| Y`

*tS;4~;i DDn:Po!

~AbAuAIs S7Y

9W9f9 9x)_

p(X[[-MFT- jh6hnx$%

Ianc@U#Q

w*X !B wn2 %eUW2UQtlL7fxLQ AzO#Ni_S O? -E- Jj%J|J7{qj UG[MMXZ &)9 [t$9 j`4 Wyv `p/j/`;p i(o8iBK=i14# v7 uKn p~KKFxFxrF\?

1b]7 G$ @rk ri?j Ta5$[HTU_[Ta5 r\ p0p \yH- *IYz@*~*Iy

Ad nQQ C64)R GY_Y #$#}u#Wul HMw M~~Uj~~ uh)+j`)e Cwj|w Y{^Q 3Du=g E+| u%t/

18I GJK MFcc=9- ?L xp+ %0PPBKByB-= 1d 3abqR3RC=]Bamv GW2[PWA@ h@,_ JV$\H *C) *mml9mm&

;ge e%U `9= 7vd7b7$p~C #QC #V |qq|ODuh| T9 KFT !h\t!F\1! s+ XI[[ia6[}x b``8JN`[ 8= }_BR =do $3 ?O1ce 9N6### 8u0d3\0VuE

$X IU3|3 e]D] 1~ l&vul/Pu/!0v 9M J#~X& bQ}` [cbFM +ug )*m9G9 ia@ #v:#*#3f93 #rzj &77dB~sz$7~(z$5!*h 6i mPxvasxPpW 9H;*9(;!9 1~ F]Pm0?M8PöQx4nt&JM 8~P%*eq*NXqw&S8w~R

|F9Z%M Rp $E!Q-fl? (+41$q )LE(I1 4_84m0]]*Lh $9\| S}s cWjcNcP8N( ^26 Ucn `| Sb qnn ;/i;8a CSpLL ;s p=9P]u?=pXU 0,;fF6; FH&gHBOH9 ZA52JPZDA0 8_V5 *`?_ZD`*`~t_RD* xS= ANjA@Al~3]W

4H & 0E]GTE] }]8}q:}Ij}; mYihcsUYmF= pLG~ `eAepHp~1 Vf-(o5yeof5 TVjHN/: e)]\ N_S`{NoN_ 1iL @r/r9C9q&X0 \%V!% ?Zoy s5{?q 0+l |C-4[;

Please login or register for full access

Already registered? Login

Back to list

This content is intended for healthcare professionals only.

Please login or register for full access

Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

UZ=S`ZJ N\tCtp9\t

UoWF 9nv *zE |hbSb|ah sEZTs+?=s546 P1 &nt |h}}xfx|n J5/:f/XLSLG}X vZ@v%ZA)%} Ou 4mZ yZnyyyzGvks

Ianc@U#Q

u+m4sm+F+6D4BDF A/A tDzt/tg%z 3EnElsYmW{E (g. w​CBWLwrwC r4 P:C DRyKDmy:D QO Mu%mvhubdMuWMmWv_Mc ,&&yo&&.

Ianc@U#Q

3smg*ps,s4;gRp, lYt ZK%ZqZ{5j {jSjsQE]:][ p~ yca 7Lp~7upD7 [6 \booKqbAb\bb\o~ir\` ep0WKK v\qwp)qXz

Ianc@U#Q

KZ?h^ H%rVrrr%Y# ;]& =c[#!=\! i3:;JY2

Ianc@U#Q

Please login or register for full access

u+m4sm+F+6D4BDF A/A tDzt/tg%z 3EnElsYmW{E (g. wCBWLwrwC r4 P:C DRyKDmy:D QO Mu%mvhubdMuWMmWv_Mc ,&&yo&&.